Brilinta Tablets and Reyataz (Atazanavir Capsules)
Determining the interaction of Brilinta Tablets and Reyataz (Atazanavir Capsules) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ticagrelor together with atazanavir is generally not recommended. Combining these medications can significantly increase the blood levels of ticagrelor and increase the risk of serious or life-threatening bleeding complications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. Call your doctor promptly if you experience any unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, dizziness, or weakness during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme. In healthy volunteers, administration of ticagrelor in combination with the potent CYP450 3A4 inhibitor ketoconazole resulted in increased ticagrelor peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.4-fold and 7.3-fold, respectively, and reduced Cmax and AUC of the active metabolite by 89% and 56%, respectively.
MANAGEMENT: Concomitant use of ticagrelor with potent CYP450 3A4 inhibitors is considered contraindicated by some foreign authorities. The U.S. labeling for ticagrelor recommends avoiding use with potent CYP450 3A4 inhibitors. Labeling for itraconazole, a potent CYP450 3A4 inhibitor, specifically contraindicates use with ticagrelor.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Generic Name: ticagrelor
Brand name: Brilinta
Synonyms: Brilinta
Generic Name: atazanavir
Brand name: Reyataz
Synonyms: Reyataz
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Brilinta Tablets-Reyataz (Atazanavir Powder for Oral Suspension)
- Brilinta Tablets-Reyvow
- Brilinta Tablets-Rezira
- Brilinta Tablets-Rh(D) Immune Globulin
- Brilinta Tablets-Rheumatrex
- Brilinta Tablets-Rheumatrex Dose Pack
- Reyataz (Atazanavir Capsules)-Brimonidine
- Reyataz (Atazanavir Capsules)-Brimonidine and brinzolamide ophthalmic
- Reyataz (Atazanavir Capsules)-Brimonidine and Timolol
- Reyataz (Atazanavir Capsules)-Brimonidine and timolol ophthalmic
- Reyataz (Atazanavir Capsules)-Brimonidine ophthalmic
- Reyataz (Atazanavir Capsules)-Brimonidine Tartrate eent